中华皮肤科杂志 ›› 2017, Vol. 50 ›› Issue (4): 291-294.

• 研究报道 • 上一篇    下一篇

蕈样肉芽肿白细胞介素13及其受体表达

丁承1,王平2,刘娇3,黎钊4,李刘雨2,刘东银2,郑俊惠5,沈宏5   

  1. 1. 安徽医科大学附属杭州临床学院
    2. 杭州市第三人民医院
    3. 浙江中医药大学附属第三医院
    4. 浙江中医药大学附属杭州第三医院
    5. 杭州市第三人民医院皮肤科
  • 收稿日期:2016-06-02 修回日期:2016-11-14 出版日期:2017-04-15 发布日期:2017-03-31
  • 通讯作者: 王平 E-mail:dermwang@aliyun.com
  • 基金资助:
    动态监测惰性期蕈样霉菌病;肿瘤微环境对蕈样肉芽肿生物行为与治疗反应的影响

Expression of interleukin?13 and its receptors in mycosis fungoides

  • Received:2016-06-02 Revised:2016-11-14 Online:2017-04-15 Published:2017-03-31
  • Contact: Ping E-mail:dermwang@aliyun.com

PDF

38

赞

摘要： 目的 探讨白细胞介素13（IL?13）及其受体在蕈样肉芽肿（MF）皮损中的表达及临床意义。方法 2010 年1月至2016年3月收集杭州市第三人民医院皮肤科经临床、病理、免疫表型和（或）T细胞受体基因重排检测确诊的MF石蜡组织标本 34份，ⅠA期5例，ⅠB期9例，ⅡA期17例和ⅡB期3例。选择正常皮肤组织10份作为对照。应用免疫组化方法分别检测IL?13、IL?13Rα1及IL?13Rα2的表达。结果 IL?13、IL?13Rα1和IL?13Rα2表达于各期MF皮损组织的异形淋巴样细胞和亲表皮性淋巴样细胞，IL?13Rα2几乎高表达于所有的MF皮损组织。正常皮肤组织及淋巴细胞均不表达IL?13及其受体。随着MF病程的进展，皮损组织IL?13及其受体表达率升高。IL?13、IL?13Rα1及IL?13Rα2的表达率在Ⅰ期MF皮损（分别为10.00% ± 3.14%、21.43% ± 6.88%、31.14% ± 6.38%）均显著低于Ⅱ期MF皮损（分别为27.50% ± 11.00%、39.45% ± 9.43%、44.40% ± 11.15%），差异均有统计学意义（P < 0.05），但在ⅠA期与ⅠB期之间以及ⅡA期与ⅡB期之间差异均无统计学意义（P > 0.05）。结论 IL?13及其受体尤其是IL?13Rα2有望成为MF早期诊断和生物学行为预判的标志物。

Abstract: Ding Cheng, Wang Ping, Liu Jiao, Li Zhao, Li Liuyu, Liu Dongyin, Zheng Junhui, Shen Hong Department of Dermatology, Hangzhou Clinical College Affiliated to Anhui Medical University, Hangzhou 310009, China （Ding C, Wang P）; Department of Dermatology, Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310009, China （Liu J）; Department of Dermatology, Hangzhou Third People′s Hospital, Hangzhou 310009, China （Li Z, Li LY, Liu DY, Zheng JH, Shen H） Corresponding author: Wang Ping, Email: dermwang@aliyun.com 【Abstract】 Objective To measure the of interleukin?13 （IL?13） and its receptors in mycosis fungoides （MF） lesions, and to investigate their clinical significance. Methods A total of 34 paraffin?embedded specimens of MF, which was confirmed by clinical and histopathological features, immunophenotyping and/or T?cell receptor gene rearrangements, were collected from Hangzhou Third People′s Hospital between January 2010 and March 2016. According to the tumor?node?metastasis （TNM） staging system, 5 patients were at stageⅠA, 9 at stageⅠB, 17 at stageⅡA, and 3 at stageⅡB. Ten normal skin tissue specimens served as controls. Immunohistochemical study was conducted to measure the of IL?13, IL?13Rα1 and IL?13Rα2. Results IL?13, IL?13Rα1 and IL?13Rα2 were all expressed in atypical lymphoid cells and epidermotropic lymphoid cells in MF lesions at various stages. IL?13Rα2 was highly expressed in all the MF lesions. None of IL?13 and its receptors were expressed in normal skin tissues and lymphocytes. The rates of IL?13 and its receptors in MF lesions increased along with the progression of MF. Additionally, the rates of IL?13 （10.00% ± 3.14%）, IL?13Rα1 （21.43% ± 6.88%） and IL?13Rα2 （31.14% ± 6.38%） significantly decreased in MF lesions at stageⅠ compared with those at stageⅡ （27.50% ± 11.00%, 39.45% ± 9.43%, 44.40% ± 11.15%, respectively, all P < 0.05）, but no significant differences were observed between stageⅠA andⅠB, or between stageⅡA andⅡB （P > 0.05）. Conclusion IL?13 and its receptors, especially IL?13Rα2, may be expected to serve as biomarkers for early diagnosis of MF and prediction of its biological behaviors.